Related Experiment Video
Updated: Jan 8, 2026
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
Current State of Pediatric Hyperlipidemia: Epidemiology, Management, and Emerging Therapies
Jaishkar Ramesh1, Ritu Tated2, Siddharth Pravin Agrawal3
1From the Department of Medicine, Texila American University, Providence, Guyana.
Insights
Pediatric hyperlipidemia, including familial hypercholesterolemia, is a growing concern. Early screening and statin therapy are key to preventing long-term cardiovascular disease in children.
Area of Science:
- Pediatric Endocrinology
- Cardiovascular Health
- Public Health
Background:
- Hyperlipidemia in children is a significant public health issue, driven by genetic factors like familial hypercholesterolemia and secondary causes such as obesity and diabetes.
- Unmanaged childhood dyslipidemia can lead to premature atherosclerosis and cardiovascular disease in adulthood.
- Current guidelines recommend universal lipid screening at ages 9-11 and late adolescence, with targeted screening for high-risk children.
Purpose of the Study:
- To review the current landscape of pediatric hyperlipidemia, including causes, screening recommendations, and therapeutic approaches.
- To highlight the role of lifestyle modifications and pharmacologic treatments, particularly statins, in managing childhood dyslipidemia.
- To discuss challenges and recent advancements in the treatment of pediatric hyperlipidemia.
Main Methods:
- Literature review of pediatric dyslipidemia, focusing on screening guidelines, etiology, and treatment modalities.
- Analysis of the efficacy and safety profiles of various lipid-lowering agents in pediatric populations.
- Examination of recent therapeutic advancements, including novel drug approvals.
Main Results:
- Familial hypercholesterolemia affects approximately 1 in 250 children, necessitating early detection.
- Lifestyle modification is the primary treatment, with pharmacologic intervention (primarily statins) considered for elevated low-density lipoprotein levels from age 10.
- Statins demonstrate a favorable safety profile, achieving significant low-density lipoprotein reductions (20-50%).
- Other agents like ezetimibe and PCSK9 inhibitors are used for specific conditions such as familial hypercholesterolemia or severe hypertriglyceridemia.
Conclusions:
- Effective management of pediatric hyperlipidemia is crucial for preventing adult cardiovascular disease.
- Early screening and timely intervention, including lifestyle changes and pharmacotherapy, are essential.
- Recent approvals of agents like PCSK9 inhibitors offer new therapeutic options for complex cases.
Abstract:
Hyperlipidemia in children is an increasingly recognized public health concern. Both primary genetic disorders-notably familial hypercholesterolemia, which affects roughly 1 in 250 children-and secondary factors like obesity, diabetes, hypothyroidism, and nephrotic syndrome contribute to pediatric dyslipidemia. Unmanaged childhood hyperlipidemia can track into adulthood and drive premature atherosclerosis and cardiovascular disease. The American Academy of Pediatrics and National Heart, Lung, and Blood Institute recommend universal lipid screening at ages 9-11 years and again in late adolescence, with earlier targeted screening for high-risk children. Lifestyle modification is first-line therapy. When lifestyle measures are insufficient, pharmacologic treatment is considered from around 10 years of age for those with markedly elevated low-density lipoprotein or additional risk factors. Statins are the cornerstone, achieving 20-50% reductions in low-density lipoprotein levels with a favorable safety profile in children. Other agents, including ezetimibe, bile acid sequestrants, fibrates, omega-3 fish oils, and newer monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, are used in select cases such as familial hypercholesterolemia or severe hypertriglyceridemia. Managing pediatric hyperlipidemia also entails overcoming challenges. Recent advances include the approval of proprotein convertase subtilisin/kexin type 9 inhibitors for pediatric use.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution